More recent data suggest that soluble oligomeric Aβ is more AD-relevant than extracellular Aβ, however EGF treatment did not modulate soluble oligomeric Aβ levels (Fig. 5e, Student’s t-test). Here, EGF is linked to Alzheimer disease.